Multiple Dose Pharmacokinetics of Intranasal Ketamine
This is an open label, single-center study of the pharmacokinetic and safety profile of repeat doses of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.
|Study Design:||Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||An Open Label, Single Center Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Administrations of 30 mg PMI-150 (Intranasal Ketamine) in Healthy Adult Volunteers|
- pharmacokinetics [ Time Frame: multiple ] [ Designated as safety issue: No ]
|Study Start Date:||June 2007|
|Study Completion Date:||August 2007|
|Primary Completion Date:||August 2007 (Final data collection date for primary outcome measure)|
Experimental: Treatment A
Drug: intranasal ketamine
To examine safety and characterize the repeat dosing plasma profile, effect on absorption, and accumulation following repeated administration of 30 mg doses of PMI-150 (intranasal ketamine) to healthy adult volunteers.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00519987
|Study Director:||Javelin Pharmaceuticals||Javelin Pharmaceuticals|